beyond glp-1 The Expanding Universe of Medications: A Revolution Diabetes and Weight Loss GLP-1-based therapies for diabetes, obesity

10.1016/j.colsurfb.2018.09.065 Colloids Surf B Biointerfaces

Buckley et al, 2020) As of January 2021, the FDA had not approved any medications for tocolysis

However, WADA is currently monitoring and evaluating the use of GLP-1 agonists by athletes to determine if they should be prohibited in the future

Pfizer has been developing danuglipron , an oral glucagon-like peptide-1 (GLP-1) receptor agonist designed for weight management and type 2 diabetes treatment

The bridge program will allow enrollees in Medicare, the federal health program for adults 65 and older, to get weight-loss drugs at prices negotiated under President Donald Trump's most favored nation agreements with Eli Lilly and Novo Nordisk

Transl Psychiatry 15 , 65 (2025)